Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.45 |
| ▸ | KDM6B | O15054 | 5/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581046 | 1.00 | KDM4C (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29581088 | 0.86 | KDM4C (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL22189458 | 0.86 | KDM4C (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL4951259 | 0.85 | KDM4C (0.56) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL22189692 | 0.82 | L3MBTL1 (0.56) | KDM4EL3MBTL1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6276352 | 0.81 | KDM4C (0.45) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL22189337 | 0.77 | KDM4E (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29581291 | 0.77 | KDM4E (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL4872353 | 0.77 | TSHR (0.72) | KMT2AALDH1A1MAPTTSHRCYP1A2 | |
| SCHEMBL22189428 | 0.77 | LTA4H (0.41) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-114126597-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3906024-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200216417-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-07-09 | — | — | US | disclosed |
| WO-2020142742-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216417-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216417-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.